Research chemicalResearch chemicalPsychedelicTryptamine

5-MeO-MiPT (Moxy)

Also known as Moxy · 5-methoxy-N-methyl-N-isopropyltryptamine

Written by enwyReviewed 4 Aug 20262 sources0 comments

5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine, Moxy) is a synthetic psychedelic tryptamine described by Shulgin. It is used non-medically for psychedelic and tactile/body effects. Human data are anecdotal; potency and safety are not established, and dose sensitivity varies widely, with a narrow margin before overwhelming effects.

01 Overview

5-MeO-MiPT, nicknamed Moxy, is a 5-methoxylated tryptamine reported to produce a psychedelic experience with notable body and tactile effects alongside visuals. Users describe a stimulating, sometimes aphrodisiac character. It circulates as a research chemical.

No controlled human studies exist. Reported potency is high and the dose-response is described as steep, so small increases can markedly intensify effects; individual sensitivity varies considerably. Difficult psychological reactions and sympathomimetic effects are reported, especially at higher doses.

02 Mechanism

Serotonin 5-HT receptor agonist acting at 5-HT2A and other subtypes; 5-methoxy tryptamines also have notable 5-HT1A activity.

03 Dosing

Tier	Dose	Route	Notes
Threshold	2–4 mg	Oral	Approximate; steep dose-response reported.
Common	4–8 mg	Oral	Onset ~20-45 min, duration ~4-6 h. Not clinically validated.
Strong	8–12 mg	Oral	Small increases can strongly intensify effects.

04 Effects

Effect	Magnitude	Evidence
Tactile / body effectsPronounced physical and tactile sensations are a characteristic feature.		Anecdotal
Visual effectsVisual enhancement and patterning reported, generally milder than 4-hydroxy tryptamines.		Anecdotal
Stimulation and euphoriaEnergetic, mood-elevating, sometimes aphrodisiac quality reported.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Insomnia / muscle tensionBody load, jaw tension and difficulty sleeping reported.	Mild	Common	Anecdotal
Anxiety and overstimulationAnxiety, agitation or panic, more likely given the steep dose-response.	Moderate	Common at higher doses	Anecdotal
Cardiovascular stimulationElevated heart rate and blood pressure, sometimes marked.	Moderate	Common	Anecdotal

06 Legal status

United Kingdom

Class A / tryptamine controls

Covered by UK tryptamine provisions. · as of Jan 2026

United States

Not federally scheduled by name; possible Federal Analogue Act exposure. · as of Jan 2026

07 References

TiHKAL: The ContinuationShulgin & Shulgin, 1997

New psychoactive substances monitoringEUDA (formerly EMCDDA)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.